secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001372514-24-000105
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials
--------------------------------------------------------------------------------

- Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.
- Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.
- Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.
- Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.
- Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/0001372514-24-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000105/kprx-20240809.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer